Performance of the eclipse monitor unit objective tool utilizing volumetric modulated arc therapy for rectal cancer.
Eclipse TPS
MU Objective tool
Progressive resolution optimizer
Rectal cancer
VMAT
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
03
09
2018
revised:
09
11
2018
accepted:
07
02
2019
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
ppublish
Résumé
To assess the performance of the monitor unit (MU) Objective tool in Eclipse treatment planning system (TPS) utilizing volumetric modulated arc therapy (VMAT) for rectal cancer. Eclipse VMAT planning module includes a tool to control the number of MUs delivered: the MU Objective tool. This tool could be utilized to reduce the total number of MUs in rectal cancer treatments. 20 rectal cancer patients were retrospectively studied using VMAT and the MU Objective tool. The baseline plan for each patient was selected as the one with no usage of the MU Objective tool. The number of MUs of this plan was set to be the reference number of MUs (MU Average relative differences in MU number obtained was 10% for Max MU values of 30% and 60% of MU A 10% reduction in the MU number could be obtained without an alteration of PTV coverage and OARs doses for rectal cancer.
Sections du résumé
AIM
OBJECTIVE
To assess the performance of the monitor unit (MU) Objective tool in Eclipse treatment planning system (TPS) utilizing volumetric modulated arc therapy (VMAT) for rectal cancer.
BACKGROUND
BACKGROUND
Eclipse VMAT planning module includes a tool to control the number of MUs delivered: the MU Objective tool. This tool could be utilized to reduce the total number of MUs in rectal cancer treatments.
MATERIALS AND METHODS
METHODS
20 rectal cancer patients were retrospectively studied using VMAT and the MU Objective tool. The baseline plan for each patient was selected as the one with no usage of the MU Objective tool. The number of MUs of this plan was set to be the reference number of MUs (MU
RESULTS
RESULTS
Average relative differences in MU number obtained was 10% for Max MU values of 30% and 60% of MU
CONCLUSIONS
CONCLUSIONS
A 10% reduction in the MU number could be obtained without an alteration of PTV coverage and OARs doses for rectal cancer.
Identifiants
pubmed: 30858766
doi: 10.1016/j.rpor.2019.02.004
pii: S1507-1367(19)30019-7
pmc: PMC6395848
doi:
Types de publication
Journal Article
Langues
eng
Pagination
227-232Références
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8
pubmed: 12694826
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1195-203
pubmed: 15990025
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7
pubmed: 16618572
Med Phys. 2008 Jan;35(1):310-7
pubmed: 18293586
Acta Oncol. 2009;48(2):227-32
pubmed: 18855157
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):252-9
pubmed: 19362244
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):610-5
pubmed: 19427560
Radiother Oncol. 2009 Nov;93(2):226-33
pubmed: 19765846
Radiother Oncol. 2010 Jan;94(1):67-70
pubmed: 20022395
J Appl Clin Med Phys. 2009 Dec 03;11(1):3114
pubmed: 20160684
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):628-36
pubmed: 21277109
Br J Radiol. 2011 Nov;84(1007):967-96
pubmed: 22011829
Med Phys. 2011 Nov;38(11):5863-72
pubmed: 22047350
J Appl Clin Med Phys. 2013 May 06;14(3):4114
pubmed: 23652245
Technol Cancer Res Treat. 2014 Jun;13(3):233-42
pubmed: 24066951
Phys Med. 2014 May;30(3):296-300
pubmed: 24076257
Rep Pract Oncol Radiother. 2013 Feb 04;18(4):201-8
pubmed: 24416554
Phys Med. 2014 Jun;30(4):497-502
pubmed: 24613513
Sci Rep. 2015 Dec 18;5:18453
pubmed: 26679747
Br J Radiol. 2016;89(1060):20150970
pubmed: 26828971
Phys Med. 2017 Mar;35:73-80
pubmed: 28228330
Rep Pract Oncol Radiother. 2018 Mar-Apr;23(2):121-125
pubmed: 29556140